Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.
Laouénan C, Marcellin P, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hézode C, Carrat F, Nicot F, Peytavin G, Mentré F, Guedj J. Laouénan C, et al. Among authors: serfaty l. Antimicrob Agents Chemother. 2014 Sep;58(9):5332-41. doi: 10.1128/AAC.02611-14. Epub 2014 Jun 30. Antimicrob Agents Chemother. 2014. PMID: 24982076 Free PMC article. Clinical Trial.
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial.
Fartoux L, Degos F, Trépo C, Goria O, Calès P, Tran A, Buffet C, Poynard T, Capron D, Raabe JJ, Roulot D, Naveau S, Grange JD, Poupon RE, Poupon R, Serfaty L. Fartoux L, et al. Among authors: serfaty l. Clin Gastroenterol Hepatol. 2007 Apr;5(4):502-7. doi: 10.1016/j.cgh.2006.10.016. Epub 2007 Jan 29. Clin Gastroenterol Hepatol. 2007. PMID: 17261383 Clinical Trial.
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S; PROVE2 Study Team. Hézode C, et al. N Engl J Med. 2009 Apr 30;360(18):1839-50. doi: 10.1056/NEJMoa0807650. N Engl J Med. 2009. PMID: 19403903 Free article. Clinical Trial.
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, Drenth JP, Serfaty L, De Backer K, Van Heeswijk R, Luo D, Picchio G, Beumont M. Marcellin P, et al. Among authors: serfaty l. Gastroenterology. 2011 Feb;140(2):459-468.e1; quiz e14. doi: 10.1053/j.gastro.2010.10.046. Epub 2010 Oct 26. Gastroenterology. 2011. PMID: 21034744 Clinical Trial.
245 results